Published in Gynecol Oncol on September 27, 2007
Comparison of outcomes between radical hysterectomy followed by tailored adjuvant therapy versus primary chemoradiation therapy in IB2 and IIA2 cervical cancer. J Gynecol Oncol (2012) 0.93
Cost-utility analysis of treatments for stage IB cervical cancer. J Gynecol Oncol (2014) 0.90
Treatment patterns of FIGO Stage IB2 cervical cancer: a single-institution experience of radical hysterectomy with individualized postoperative therapy and definitive radiation therapy. Gynecol Oncol (2008) 0.86
Brachytherapy versus radical hysterectomy after external beam chemoradiation: a non-randomized matched comparison in IB2-IIB cervical cancer patients. World J Surg Oncol (2009) 0.86
Does the Robotic Platform Reduce Morbidity Associated With Combined Radical Surgery and Adjuvant Radiation for Early Cervical Cancers? Int J Gynecol Cancer (2016) 0.75
Cost-effectiveness of radical hysterectomy with adjuvant radiotherapy versus radical radiotherapy for FIGO stage IIB cervical cancer. Onco Targets Ther (2016) 0.75
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med (2007) 7.31
Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer (2006) 5.87
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin (2012) 5.58
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol (2012) 3.51
Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol (2005) 3.31
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis (2012) 3.15
Forecasting the prevalence of pelvic floor disorders in U.S. Women: 2010 to 2050. Obstet Gynecol (2009) 3.08
Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol (2006) 3.08
Histological dating of timed endometrial biopsy tissue is not related to fertility status. Fertil Steril (2004) 3.03
Risk of cervical cancer associated with extending the interval between cervical-cancer screenings. N Engl J Med (2003) 2.72
The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis (2003) 2.72
Absence of secretory endometrium after false-positive home urine luteinizing hormone testing. Fertil Steril (2004) 2.59
Incidence and risk factors for stroke in pregnancy and the puerperium. Obstet Gynecol (2005) 2.50
Acute myocardial infarction in pregnancy: a United States population-based study. Circulation (2006) 2.49
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) (2009) 2.42
Predicting the number of women who will undergo incontinence and prolapse surgery, 2010 to 2050. Am J Obstet Gynecol (2011) 2.36
Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol (2004) 2.32
Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev (2013) 2.18
Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. Obstet Gynecol (2013) 2.17
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine (2008) 2.09
Dissemination of Evidence-based Practice Center reports. Ann Intern Med (2005) 2.05
Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma. Cancer (2009) 1.98
Predictors of pregnancy in women with polycystic ovary syndrome. J Clin Endocrinol Metab (2009) 1.90
Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA (2003) 1.89
Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology. Gynecol Oncol (2006) 1.75
Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. J Clin Oncol (2011) 1.73
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin (2009) 1.66
Cervical Cancer Screening in Average-Risk Women: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med (2015) 1.63
Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS). J Natl Cancer Inst (2006) 1.58
Cost effectiveness of concurrent gemcitabine and cisplatin with radiation followed by adjuvant gemcitabine and cisplatin in patients with stages IIB to IVA carcinoma of the cervix. Gynecol Oncol (2012) 1.58
The Pregnancy in Polycystic Ovary Syndrome study: baseline characteristics of the randomized cohort including racial effects. Fertil Steril (2006) 1.56
Risk of acute thromboembolic events with oral contraceptive use: a systematic review and meta-analysis. Obstet Gynecol (2013) 1.56
A pilot Phase II trial of concurrent radiotherapy, chemotherapy, and hyperthermia for locally advanced cervical carcinoma. Cancer (2003) 1.56
The role of lymphadenectomy in the management of preoperative grade 1 endometrial carcinoma. Gynecol Oncol (2009) 1.54
Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reduction. Cancer (2010) 1.53
FDG-PET for management of cervical and ovarian cancer. Gynecol Oncol (2005) 1.52
Uterine artery embolization for treatment of leiomyomata: long-term outcomes from the FIBROID Registry. Obstet Gynecol (2008) 1.49
The impact of postoperative nausea and vomiting prophylaxis with dexamethasone on postoperative wound complications in patients undergoing laparotomy for endometrial cancer. Anesth Analg (2013) 1.45
Nicotine replacement and behavioral therapy for smoking cessation in pregnancy. Am J Prev Med (2007) 1.44
Cost comparison of strategies for the management of venous thromboembolic event risk following laparotomy for ovarian cancer. Gynecol Oncol (2011) 1.44
HPV vaccines: now that they're here, how do we maximize their benefit? Contraception (2006) 1.41
Cost comparison among robotic, laparoscopic, and open hysterectomy for endometrial cancer. Obstet Gynecol (2010) 1.31
Fertility patients' views about frozen embryo disposition: results of a multi-institutional U.S. survey. Fertil Steril (2008) 1.30
Total testosterone assays in women with polycystic ovary syndrome: precision and correlation with hirsutism. J Clin Endocrinol Metab (2010) 1.29
An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC). Gynecol Oncol (2009) 1.29
Cervical cancer trends in the United States: a 35-year population-based analysis. J Womens Health (Larchmt) (2012) 1.28
Effect of hysterectomy with ovarian preservation on ovarian function. Obstet Gynecol (2011) 1.28
Abnormal outcomes following cervical cancer screening: event duration and health utility loss. Med Decis Making (2007) 1.28
Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol (2007) 1.26
The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer. Gynecol Oncol (2007) 1.24
The FIBROID Registry: symptom and quality-of-life status 1 year after therapy. Obstet Gynecol (2005) 1.22
Adherence to nicotine replacement therapy among pregnant smokers. Nicotine Tob Res (2009) 1.21
Epithelial ovarian cancer. J Natl Compr Canc Netw (2011) 1.16
Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study. Gynecol Oncol (2006) 1.15
A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer. Gynecol Oncol (2009) 1.15
Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene. J Clin Endocrinol Metab (2007) 1.14
Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis. Cost Eff Resour Alloc (2008) 1.14
Ovarian cancer, version 2.2013. J Natl Compr Canc Netw (2013) 1.13
Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment. Gynecol Oncol (2009) 1.12
Retrospective review of an intraoperative algorithm to predict lymph node metastasis in low-grade endometrial adenocarcinoma. Gynecol Oncol (2011) 1.11
Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence. J Urol (2009) 1.10
Cost-effectiveness of extending cervical cancer screening intervals among women with prior normal pap tests. Obstet Gynecol (2006) 1.09
Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study. Gynecol Oncol (2009) 1.09
Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it? Gynecol Oncol (2008) 1.09
Ovarian cancer, version 3.2012. J Natl Compr Canc Netw (2012) 1.08
Management of adnexal mass. Evid Rep Technol Assess (Full Rep) (2006) 1.08
Timing of end-of-life care discussion with performance on end-of-life quality indicators in ovarian cancer. Gynecol Oncol (2013) 1.07
Cost-minimization analysis of robotic-assisted, laparoscopic, and abdominal sacrocolpopexy. J Minim Invasive Gynecol (2010) 1.07
Cost-effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence. J Urol (2009) 1.06
Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2016) 1.06
A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer. Gynecol Oncol (2012) 1.05
Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer. Gynecol Oncol (2012) 1.04
Ovarian cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2008) 1.04
Challenges and solutions for recruiting pregnant smokers into a nicotine replacement therapy trial. Nicotine Tob Res (2006) 1.01
Leiomyoma-related hospitalization and surgery: prevalence and predicted growth based on population trends. Am J Obstet Gynecol (2011) 1.00
Accuracy and cost-effectiveness of cervical cancer screening by high-risk human papillomavirus DNA testing of self-collected vaginal samples. J Low Genit Tract Dis (2010) 0.99
Projecting the need for gynecologic oncologists for the next 40 years. Obstet Gynecol (2010) 0.99
Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes. Gynecol Oncol (2009) 0.98
Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol (2008) 0.98
Should older women have antepartum testing to prevent unexplained stillbirth? Obstet Gynecol (2004) 0.97
Clinical and pathologic correlates in surgical stage II endometrial carcinoma. Obstet Gynecol (2007) 0.96
Cost-effectiveness analysis of annual screening strategies for endometrial cancer. Am J Obstet Gynecol (2009) 0.96
Pap testing and sexual activity among young women in the United States. Obstet Gynecol (2009) 0.95